| |
| |
| Exchange: |
Nasdaq National Market |
| Security
Type: |
Common |
| Shares
Out: |
66,921,000 |
| Market
Cap: |
2.83(B) |
| Last
Volume: |
1,212,774 |
Avg
Vol: |
1,001,263 |
| 52
Week Range: |
$38.26 - $89.25 |
|
| Level
I Sector: |
Health Care |
| Level
II Sector: |
Drugs |
| Level
III Sector: |
Diagnostic Substances |
|
Member Indexes:
|
| |
NASDAQ COMPOSITE |
|
NASDAQ NNM COMPOSITE |
|
Rankings:
|
|
| Insider 3 Months : - |
| Insider 6 Months : - |
| Insider 3/6 Months : - |
|
| Guru Rank Number : - |
| Guru Rank Value : - |
| Guru Occurances : - |
|
|
|
|
|
| |
|
Company Profile QuidelOrtho is engaged in the development, manufacturing and marketing of diagnostic testing solutions. Co. provides diagnostic testing solutions under various brand names, including, among others, the following: Quidel®, QuickVue®, QuickVue+®, Sofia®, Triage®, Solana®, Virena®, MicroVue™, Lyra®, FreshCells™, D3®, FastPoint®, ReadyCells®, Super E-Mix™, InflammaDry®, AdenoPlus®, ELVIRA®, ELVIS® and Thyretain®. Co.'s diagnostic testing solutions are separated into its four product categories: rapid immunoassay, cardiometabolic immunoassay, molecular diagnostic solutions and specialized diagnostic solutions.
|
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
|
3m +/-:
|
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
|
Actions:
|
|
|
| B |
Buy |
| S |
Sell |
| OE |
Option
Exercised |
| A |
Acquired |
| D |
Disposed |
| AB |
Automatic
Buy |
| AS |
Automatic
Sell |
| IO |
Initial
Ownership |
|
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
| |
| |
Summary (Direct Transactions Only)  |
3 Months |
6 Months |
12 Months |
24 Months |
| Total Shares Bought |
0 |
0 |
0 |
0 |
| Total Buy Value |
$0 |
$0 |
$0 |
$0 |
| Total People Bought |
0 |
0 |
0 |
0 |
| Total Buy Transactions |
0 |
0 |
0 |
0 |
| Total Shares Sold |
0 |
0 |
0 |
0 |
| Total Sell Value |
$0 |
$0 |
$0 |
$0 |
| Total People Sold |
0 |
0 |
0 |
0 |
| Total Sell Transactions |
0 |
0 |
0 |
0 |
| End Date |
2024-02-01 |
2023-10-31 |
2023-05-02 |
2022-05-02 |
|
| Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
  Widder Kenneth J |
Director |
– • – |
2021-05-12 |
4 |
OE |
$0.00 |
$0 |
D/D |
1,040 |
15,456 |
|
- |
|
| Rhoads Ann D |
Director |
– • – |
2021-05-12 |
4 |
OE |
$0.00 |
$0 |
D/D |
624 |
624 |
|
- |
|
| Strobeck Matthew |
Director |
– • – |
2021-05-12 |
4 |
OE |
$0.00 |
$0 |
D/D |
1,040 |
4,909 |
|
- |
|
| Polan Mary Lake Ph D |
Director |
– • – |
2021-05-12 |
4 |
OE |
$0.00 |
$0 |
D/D |
1,040 |
25,369 |
|
- |
|
| Slacik Charles P |
Director |
– • – |
2021-05-12 |
4 |
OE |
$0.00 |
$0 |
D/D |
1,250 |
12,465 |
|
- |
|
| Ordonez Kathy |
Director |
– • – |
2021-05-12 |
4 |
OE |
$0.00 |
$0 |
D/D |
1,040 |
2,896 |
|
- |
|
| Ferenczy William J. |
SVP, Cardio/Metabolic Unit |
• – – |
2021-05-03 |
4 |
S |
$105.74 |
$84,909 |
D/D |
(803) |
5,324 |
|
-38% |
|
| Ferenczy William J. |
SVP, Cardio/Metabolic Unit |
• – – |
2021-05-03 |
4 |
OE |
$23.41 |
$18,798 |
D/D |
803 |
6,127 |
|
- |
|
| Ferenczy William J. |
SVP, Cardio/Metabolic Unit |
• – – |
2021-03-30 |
4 |
D |
$126.39 |
$27,300 |
D/D |
(216) |
5,324 |
|
- |
|
| Ferenczy William J. |
SVP, Cardio/Metabolic Unit |
• – – |
2021-03-30 |
4 |
OE |
$0.00 |
$0 |
D/D |
434 |
5,540 |
|
- |
|
| Ferenczy William J. |
SVP, Cardio/Metabolic Unit |
• – – |
2021-03-17 |
4 |
S |
$136.05 |
$1,006,837 |
D/D |
(7,400) |
5,106 |
|
4% |
|
| Ferenczy William J. |
SVP, Cardio/Metabolic Unit |
• – – |
2021-03-17 |
4 |
OE |
$15.40 |
$76,390 |
D/D |
4,601 |
12,506 |
|
- |
|
| Wilkins Joseph D Jr. |
Director |
– • – |
2021-02-26 |
3 |
IO |
$0.00 |
$0 |
D/D |
0 |
1 |
|
-26% |
|
| Kroll Werner |
SVP, R&D |
• – – |
2021-02-24 |
4 |
S |
$173.71 |
$917,734 |
D/D |
(5,283) |
8,119 |
|
26% |
|
| Kroll Werner |
SVP, R&D |
• – – |
2021-02-23 |
4 |
S |
$164.59 |
$804,058 |
D/D |
(4,835) |
13,402 |
|
25% |
|
| Kroll Werner |
SVP, R&D |
• – – |
2021-02-22 |
4 |
S |
$164.11 |
$2,097,955 |
D/D |
(12,784) |
18,237 |
|
21% |
|
| Kroll Werner |
SVP, R&D |
• – – |
2021-02-22 |
4 |
OE |
$21.08 |
$556,674 |
D/D |
12,784 |
31,021 |
|
- |
|
| Bryant Douglas C |
President & CEO |
• • – |
2021-02-22 |
4 |
B |
$165.30 |
$826,500 |
D/D |
5,000 |
495,807 |
2.81 |
-21% |
|
| Steward Randall J |
Chief Financial Officer |
• – – |
2021-02-18 |
4 |
D |
$210.10 |
$1,003,228 |
D/D |
(4,775) |
15,169 |
|
- |
|
| Steward Randall J |
Chief Financial Officer |
• – – |
2021-02-18 |
4 |
A |
$0.00 |
$0 |
D/D |
9,629 |
17,565 |
|
- |
|
| Ferenczy William J. |
SVP, Cardio/Metabolic Unit |
• – – |
2021-02-18 |
4 |
D |
$210.10 |
$306,116 |
D/D |
(1,457) |
7,310 |
|
- |
|
| Ferenczy William J. |
SVP, Cardio/Metabolic Unit |
• – – |
2021-02-18 |
4 |
A |
$0.00 |
$0 |
D/D |
3,388 |
8,134 |
|
- |
|
| Gibson Karen |
SVP, Digital Health |
• – – |
2021-02-18 |
4 |
D |
$210.10 |
$353,178 |
D/D |
(1,681) |
7,812 |
|
- |
|
| Gibson Karen |
SVP, Digital Health |
• – – |
2021-02-18 |
4 |
A |
$0.00 |
$0 |
D/D |
3,388 |
8,636 |
|
- |
|
| Bryant Douglas C |
President & CEO |
• • – |
2021-02-18 |
4 |
D |
$210.10 |
$3,389,543 |
D/D |
(16,133) |
490,807 |
|
- |
|
799 Records found
|
|
Page 5 of 32 |
|
|
2.54 (6.4%) 
